A Phase 3 interventional study of dl-3-butylphthalide and dl-3-butylphthalide placebo in Stroke and Post-stroke Cognitive Impairment (PSCI), sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Fudan University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 38th largest by planned enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 62 in phase 3, reaches primary completion later than 120 of the 262 other live ones, and was the 350th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Qingdao Central Hospital · Sites in China
Ages 18–75
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 71 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,200 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
Fudan University has 7 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
68 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 68 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-stroke cognitive impairment (PSCI) refers to a clinical syndrome characterized by cognitive impairment that occurs after a stroke event and persists for at least 24 weeks. Due to the early recovery of conditions such as delirium and transient cognitive impairment after stroke, the diagnosis of PSCI often requires cognitive assessment at 12 to 24 weeks post-stroke to determine the severity of cognitive impairment. It can be classified according to the severity of cognitive impairment as post-stroke cognitive impairment no dementia (PSCIND) and post-stroke dementia (PSD). Recent large international cohort studies have reported an incidence rate of PSCI ranging from 24% to 53.4%, and patients with PSCI have a significantly higher mortality rate compared to those without cognitive impairment. Guidelines such as American Heart Association/American Society of Anesthesiologists (AHA/ASA) and the Chinese "Expert Consensus on the Management of Post-Stroke Cognitive Impairment" propose integrating cognitive impairment and stroke intervention strategies. Early comprehensive intervention and treatment for high-risk individuals after stroke, aiming to delay or prevent the progression from PSCIND to PSD, are the primary goals in the current treatment of PSCI. However, there is currently a lack of large randomized controlled trials (RCTs) for PSCI, and research is still needed to determine whether cognitive-enhancing drugs can reduce the risk of PSCI occurrence and improve outcomes and prognosis for PSCI patients. A randomized, double-blind, multicenter clinical study involving 281 non-dementia vascular cognitive impairment (VCI) patients showed that the overall cognitive scores of patients treated with donepezil for 24 weeks significantly improved compared to the placebo group.
The aim of this study is to evaluate the effectiveness of donepezil in the treatment of post-stroke cognitive impairment. It will be a multicenter, randomized, double-blind, placebo-controlled trial with a 48-week treatment duration. The study will observe the difference in PSCI incidence rate between the donepezil treatment group and the conventional stroke treatment group at 24 weeks and evaluate the improvement in post-stroke cognitive impairment after 6 months of donepezil treatment compared to conventional treatment.
This study will be conducted in two stages: the first stage (0-24 weeks) aims to assess whether donepezil can reduce the risk of PSCI occurrence and will be a multicenter, randomized, double-blind, placebo-controlled study. The second stage (24-48 weeks) aims to evaluate whether donepezil can improve the prognosis of PSCI patients and will also be a multicenter, randomized, double-blind, placebo-controlled study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
First stage:
Second stage:
Exclusion Criteria:
First stage:
Second stage:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine treatment and dl-3-butylphthalide
Drug: dl-3-butylphthalide · Drug: dl-3-butylphthalide placebo
Routine treatment and dl-3-butylphthalide Placebo
Drug: dl-3-butylphthalide · Drug: dl-3-butylphthalide placebo
First stage: Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs. Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Second stage: 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.
Also known as: DL-3-n-butylphthalide (NBP)
First stage: Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs. Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Second stage: 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks. Butylphthalide group: Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.
Also known as: NBP placebo
PSCI incidence
Compared with routine stroke treatment, the difference of the PSCI incidence at 24 weeks with butylphthalide treatment.
Time frame: 24 weeks (first stage)
vadas-cog score
Compared with routine treatment, improvement of vadas-cog scores at 24 weeks with butylphthalide treatment
Time frame: 6 months (Second stage)
Changes of Montreal Cognitive Assessment (MoCA) at 24 weeks compared with baseline
Changes of Montreal Cognitive Assessment (MoCA) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of Mini-Mental State Examination (MMSE) at 24 weeks compared with baseline
Changes of Mini-Mental State Examination (MMSE) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 24 weeks compared with baseline
Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of Hamilton Anxiety Scale (HAMA) at 24 weeks compared with baseline
Changes of Hamilton Anxiety Scale (HAMA) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of Hamilton Depression Scale (HAMD) at 24 weeks compared with baseline
Changes of Hamilton Depression Scale (HAMD) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 24 weeks compared with baseline
Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of Clinical Dementia Rating (CDR) at 24 weeks compared with baseline
Changes of Clinical Dementia Rating (CDR) at 24 weeks compared with baseline
Time frame: 24 weeks (first stage)
Changes of infarct volume by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.
Changes of infarct volume by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.
Time frame: 24 weeks (first stage)
Changes of infarct location by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.
Changes of infarct location by cranial magnetic resonance imaging (MRI) at 24 weeks after treatment with butylphthalein compared with routine stroke treatment.
Time frame: 24 weeks (first stage)
stroke recurrence
Difference in stroke recurrence rate of butylphthalein treatment compared with routine stroke treatment at 24 weeks
Time frame: 24 weeks (first stage)
Changes of modified Rankin Scale score (mRS) at 24 weeks compared with baseline.
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS is a range from 0-6. 0=No symptoms, 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead
Time frame: 24 weeks (first stage)
Changes of Montreal Cognitive Assessment (MoCA) at 48 weeks compared with baseline
Changes of Montreal Cognitive Assessment (MoCA) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes of Mini-Mental State Examination (MMSE) at 48 weeks compared with baseline
Changes of Mini-Mental State Examination (MMSE) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes cognitive domain level by Symbol Digit Modalities Test at 48 weeks compared with baselinel
Changes cognitive domain level by Symbol Digit Modalities Test at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes cognitive domain level by Trail Making Test at 48 weeks compared with baseline.
Changes cognitive domain level by Trail Making Test at 48 weeks compared with baseline.
Time frame: 48 weeks (second stage)
Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 48 weeks compared with baseline
Changes of Neuropsychiatric Inventory Questionnaire (NPI-Q) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes of Hamilton Anxiety Scale (HAMA) at 48 weeks compared with baseline
Changes of Hamilton Anxiety Scale (HAMA) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes of Hamilton Depression Scale (HAMD) at 48 weeks compared with baseline
Changes of Hamilton Depression Scale (HAMD) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes of Clinical Dementia Rating (CDR) at 48 weeks compared with baseline
Changes of Clinical Dementia Rating (CDR) at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 48 weeks compared with baseline
Changes of 23-item version of Alzheimer's Disease Cooperative Study- activities of daily living scale (ADCS-ADL23) for activities of daily living at 48 weeks compared with baseline
Time frame: 48 weeks (second stage)
stroke recurrence
Difference in stroke recurrence rate of butylphthalein treatment compared with routine stroke treatment at 48 weeks
Time frame: 48 weeks (second stage)
Changes of mRS at 48 weeks compared with baseline.
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS is a range from 0-6. 0=No symptoms, 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead
Time frame: 48 weeks (second stage)
Incidence of Treatment-Emergent Adverse Events [Safety]
Incidence of Treatment-Emergent Adverse Events \[Safety\]
Time frame: 12 weeks, 24 weeks, 36 weeks and 48 weeks
Dropout rates and reasons [Safety]
Dropout rates and reasons \[Safety\]
Time frame: 12 weeks, 24 weeks, 36 weeks and 48 weekss
Start is estimated for Apr 2024; primary completion for Dec 2026, 32 months later.
Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 32 months is below that.
Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Butylphthalide